Af­ter abrupt­ly pulling its mar­ket­ing ap­pli­ca­tion, DBV may be left with peanuts in race against Aim­mune

7 years ago
R&D
Pharma

FDA hands As­traZeneca and Mer­ck a snap OK to mar­ket Lyn­parza in front­line ovar­i­an can­cer, mark­ing a new stan­dard in ...

7 years ago
Pharma

That’s got­ta hurt. FDA turns thumbs down on Spec­trum’s 'break­through' pitch for can­cer drug pozi­o­tinib and shares ...

7 years ago
R&D

Vivek Ra­maswamy bags op­tion rights on Dai­ichi’s pipeline drugs; Achillion drops a lead pro­gram; Zio­pharm cre­ates ...

7 years ago
News Briefing

River­Vest ready to roll with Fund IV af­ter clos­ing the till with $184M

7 years ago
Financing

John John­son is back try­ing his hand as a turn­around artist for a trou­bled biotech. Can he win this time?

7 years ago
People

Gilead dan­gles $105M in quick cash to sign Schol­ar Rock to a dis­cov­ery deal for its grow­ing NASH pipeline

7 years ago
R&D
Pharma

Roche, Alex­ion ripe for show­down in a race to treat rare CNS dis­or­der

7 years ago
R&D

An­nex­on grabs $75M to pay for push in­to PhII stud­ies for C1q drugs

7 years ago
Financing

With can­cer in fo­cus, Am­gen taps Mol­e­c­u­lar Part­ner­s' pre­clin­i­cal im­mune-on­col­o­gy as­set for $50M up­front

7 years ago
Pharma

Aim­ing to shed last-place rep, Eli Lil­ly touts its PhI­II pipeline and promis­es a faster game in R&D

7 years ago
R&D

Ready to con­sum­mate its Shire buy­out, Take­da plans US dual list­ing while NYSE los­es a ma­jor phar­ma to Nas­daq

7 years ago
Pharma

GSK, Pfiz­er to cre­ate con­sumer health pow­er­house un­der JV — then spin it out

7 years ago
Financing

Lit­tle Tetra is prep­ping a PhII Alzheimer’s study. In fact, they just got $40M to fund it

7 years ago
Startups

Sur­face On­col­o­gy reins back its lead pro­gram af­ter track­ing low-dose tox­i­c­i­ty for CD47 drug

7 years ago
R&D

Reimag­in­ing med­i­cine? No­var­tis wraps phar­ma’s first big glob­al pot deal

7 years ago
Pharma

No­vo helps birth start­up ad­vanc­ing an As­traZeneca castoff with $15M; Japan's Fu­ji Phar­ma wa­gers $50M on Alvotech's ...

7 years ago
News Briefing

No­var­tis CAR-T chief drops out of Big Phar­ma, joins the great mi­gra­tion to a fa­vorite biotech des­ti­na­tion

7 years ago
People

Tar­get­ing un­der­ly­ing cause of PAH, Cam­bridge spin­out Mor­phogen-IX rais­es about $23M in Se­ries B

7 years ago
Financing
Startups

En­tra­da launch­es to­day, tak­ing a $59M shot at some tough in­tra­cel­lu­lar tar­gets

7 years ago
Financing
Startups

Jonathan Lim is­n't ready to say much about his new start­up, but he does have $42M for it

7 years ago
Financing
Startups

Sec­ond dose of Sophiris' prostate can­cer drug proves fu­tile, shares crash

7 years ago
R&D

Sanofi is con­cen­trat­ing its forces in Cam­bridge hub, ink­ing a mas­sive lease for 2,700 staffers

7 years ago
Pharma

Fi­bro­Gen, As­traZeneca score Chi­na ap­proval for ane­mia drug ahead of piv­otal US da­ta

7 years ago
China
Pharma
First page Previous page 987988989990991992993 Next page Last page
A service from the Financial Times